Literature DB >> 23978999

Trends in plasma HIV-RNA suppression and antiretroviral resistance in British Columbia, 1997-2010.

Angela Cescon1, Steve Kanters, Chanson J Brumme, Katherine J Lepik, Jamie I Forrest, Mark Hull, Hasina Samji, Bohdan Nosyk, P Richard Harrigan, Robert S Hogg, Julio S G Montaner.   

Abstract

OBJECTIVES: To examine temporal trends in plasma viral load (pVL) suppression and antiretroviral resistance from 1997 to 2010 in British Columbia (BC), Canada, and determine characteristics, pVL ranges, and resistance profiles of HIV-positive individuals with unsuppressed pVL in 2010.
METHODS: HIV-positive individuals ≥19 years old in the provincial database at the BC Centre for Excellence in HIV/AIDS were included. Virological suppression was defined as 2 consecutive pVL <500 copies per milliliter within each calendar year. Temporal trends were evaluated using the Cochran-Armitage test. Persons with suppressed vs. unsuppressed pVL in 2010 were compared using the Pearson χ² or Fisher exact test (categorical variables) and the Wilcoxon rank-sum test (quantitative variables), including unsuppressed individuals only if they were on antiretroviral therapy (ART) in 2010 or their baseline CD4 count was <350 cells per cubic millimeter or <500 cells per cubic millimeter, in separate analyses.
RESULTS: The proportion of individuals with suppressed pVL increased from 24% to 80% (P < 0.001). In comparative analyses, individuals with unsuppressed pVL (877 of 6142) were more likely to be female (30% vs. 16%), younger (median, 43 vs. 48 years), have injection drug use history (38% vs. 30%), report Aboriginal ancestry (30% vs. 16%), and have hepatitis C coinfection (57% vs. 34%) (all P < 0.001). Similar patterns were observed using the <500 cells per cubic millimeter CD4 cutoff. The median pVL of all unsuppressed individuals in 2010 was 12,896 copies per milliliter (interquartile range, 1495-47,763).
CONCLUSIONS: The proportion of individuals achieving pVL suppression in BC has increased markedly since 1997; however, further efforts are needed to maximize the individual and societal benefits of modern antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23978999      PMCID: PMC4266465          DOI: 10.1097/QAI.0b013e3182a8efc3

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  32 in total

1.  Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users.

Authors:  Sasha Uhlmann; M-J Milloy; Thomas Kerr; Ruth Zhang; Silvia Guillemi; David Marsh; Robert S Hogg; Julio S G Montaner; Evan Wood
Journal:  Addiction       Date:  2010-03-10       Impact factor: 6.526

Review 2.  The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic.

Authors:  Julio S G Montaner; Robert Hogg; Evan Wood; Thomas Kerr; Mark Tyndall; Adrian R Levy; P Richard Harrigan
Journal:  Lancet       Date:  2006-08-05       Impact factor: 79.321

3.  Decline in deaths from AIDS due to new antiretrovirals.

Authors:  R S Hogg; M V O'Shaughnessy; N Gataric; B Yip; K Craib; M T Schechter; J S Montaner
Journal:  Lancet       Date:  1997-05-03       Impact factor: 79.321

4.  Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.

Authors:  R S Hogg; K V Heath; B Yip; K J Craib; M V O'Shaughnessy; M T Schechter; J S Montaner
Journal:  JAMA       Date:  1998-02-11       Impact factor: 56.272

5.  Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multi-site Canadian cohort.

Authors:  A M Cescon; C Cooper; K Chan; A K Palmer; M B Klein; N Machouf; M R Loutfy; J Raboud; A Rachlis; E Ding; V D Lima; J S G Montaner; S B Rourke; M Smieja; C Tsoukas; R S Hogg
Journal:  HIV Med       Date:  2010-11-08       Impact factor: 3.180

6.  Fully automated quantification of human immunodeficiency virus (HIV) type 1 RNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan system.

Authors:  Wolfram Schumacher; Edmund Frick; Mirko Kauselmann; Viola Maier-Hoyle; Reinier van der Vliet; Reiner Babiel
Journal:  J Clin Virol       Date:  2007-02-27       Impact factor: 3.168

7.  Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand.

Authors:  Sodsai Tovanabutra; Valerie Robison; Jeerang Wongtrakul; Supaluk Sennum; Vinai Suriyanon; Duangnapa Kingkeow; Surinda Kawichai; Praijitr Tanan; Ann Duerr; Kenrad E Nelson
Journal:  J Acquir Immune Defic Syndr       Date:  2002-03-01       Impact factor: 3.731

8.  Access to health and social services for IDU: the impact of a medically supervised injection facility.

Authors:  Will Small; Natasha Van Borek; Nadia Fairbairn; Evan Wood; Thomas Kerr
Journal:  Drug Alcohol Rev       Date:  2009-07

9.  Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study.

Authors:  Julio S G Montaner; Viviane D Lima; Rolando Barrios; Benita Yip; Evan Wood; Thomas Kerr; Kate Shannon; P Richard Harrigan; Robert S Hogg; Patricia Daly; Perry Kendall
Journal:  Lancet       Date:  2010-07-16       Impact factor: 79.321

10.  Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco.

Authors:  Moupali Das; Priscilla Lee Chu; Glenn-Milo Santos; Susan Scheer; Eric Vittinghoff; Willi McFarland; Grant N Colfax
Journal:  PLoS One       Date:  2010-06-10       Impact factor: 3.240

View more
  5 in total

1.  Cohort Profile: HAART Observational Medical Evaluation and Research (HOMER) cohort.

Authors:  Sophie Patterson; Angela Cescon; Hasina Samji; Zishan Cui; Benita Yip; Katherine J Lepik; David Moore; Viviane D Lima; Bohdan Nosyk; P Richard Harrigan; Julio S G Montaner; Kate Shannon; Evan Wood; Robert S Hogg
Journal:  Int J Epidemiol       Date:  2014-03-17       Impact factor: 7.196

2.  Incarceration of people living with HIV/AIDS: implications for treatment-as-prevention.

Authors:  M-J Milloy; Julio S G Montaner; Evan Wood
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

3.  The population impact of eliminating homelessness on HIV viral suppression among people who use drugs.

Authors:  Brandon D L Marshall; Beth Elston; Sabina Dobrer; Surita Parashar; Robert S Hogg; Julio S G Montaner; Thomas Kerr; Evan Wood; M-J Milloy
Journal:  AIDS       Date:  2016-03-27       Impact factor: 4.177

4.  Continued Substance Use Among People Living With HIV-Hepatitis-C Co-Infection and Receiving Antiretroviral Therapy.

Authors:  Seth C Kalichman; Christopher Washington; Christopher Kegler; Tamar Grebler; Moira O Kalichman; Chauncey Cherry; Lisa Eaton
Journal:  Subst Use Misuse       Date:  2015-11-19       Impact factor: 2.164

5.  Improvements in HIV treatment outcomes among indigenous and non-indigenous people who use illicit drugs in a Canadian setting.

Authors:  M-J Milloy; Alexandra King; Thomas Kerr; Evan Adams; Hasina Samji; Silvia Guillemi; Evan Wood; Julio Montaner
Journal:  J Int AIDS Soc       Date:  2016-04-18       Impact factor: 5.396

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.